MUTUAL INFLUENCE OF HEART FAILURE ON THE COURSE OF TYPE 2 DIABETES MELLITUS
Keywords:
Key words: diabetes mellitus, pharmacotherapy, ischemic cardiomyopathy, hypoglycemia, multidisciplinary approach.Abstract
Abstract: Chronic heart failure (CHF) is one of the most significant medical and social pathologies characterized by a high prevalence and mortality. According to experts, CHF in Western countries occurs in 1-2% of the general population, reaching 10% in people over 70 years of age. In the Russian Federation, CHF is diagnosed in 7-10% of cases, while more than 65% of Russian patients are people over 60 years old. In the structure of mortality from diseases of the circulatory system, CHF occupies one of the leading positions 19, 13, 15, 16].Among the reasons leading to the development of CHF, arterial is traditionally considered - hypertension (AH) and coronary heart disease (CHD), which occupy the largest share in the structure of nosologies that cause the formation of heart failure (95.5% and 69.7%, respectively). The classical causes of CHF (heart defects, cardiomyopathies, myocarditis, etc.) are less common. At the same time, one of the frequent and significant diseases characterized by the early development of heart failure is type 2 diabetes mellitus (DM), which has been shown in a number of studies. In the Russian Federation, DM ranks third (15.9%) among the causes of CHF [9, 13, 14]. In addition, the occurrence and progression of heart failure in patients with DM is one of the main causes of death in this cohort of patients.
References
References:
Rosano G, Vitale C, Seferovic P. Heart Failure in Patients with Diabetes Mellitus. Card Fail Rev. 2017:3 (1):52-5. doi:10.15420/cfr.2016:20:2
Cosentino F. Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular developed in collaboration with the EASD: the task force for diabetes, pre-diabetes. and cardiovascular diseases of the European diseases Society of cardiology (ESC) and the European association for the study of diabetes (EASD). European heart journal. 2020 :41 (2):255-323.doi:10.1093/ eurheart/ehz486.
Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. circulation. 2019:140 (7):e294-e324. doi: 10.1161/CIR.0000000000000691.
Saeedi P. Petersohn I, Salpea P, et al. Global and regional diabetes prevalenceestimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, Diabetes research and clinical practice. 2019;157:107843. doi: 10.1016/j.diabres 2019.107843.
Shestakova MV, Vikulova OK, Zheleznyakova AV, et al. Diabetes epidemiology in Russia: what haschanged over the decade? Therapeutic archive 2019;91(10):4-13. (In Russ.) Shestakova M. V., Vikulova O. K., Zheleznyakova A. V., et al. Epidemiology of diabetes mellitus in the Russian Federation: what has changed over the past decade. Therapeutic archive. 2019:91(10):4-13.
Dedov II, Shestakova MV. Vikulova OK, et al. Diabetes mellitus in Russian Federation:prevalence , Morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Diabetes Mellitus. 2018 :21 (3):144-59. (In Russ) Dedov I. I. Shestakova M. V., Vikulova O. K., et al. Diabetes mellitus in the Russian Federation: prevalence, morbidity, mortality, parameters of carbohydrate metabolism and the structure of hypoglycemic therapy according to the Federal Register of Diabetes Mellitus, status 2017. Diabetes mellitus. 2018;21(3):144-59. Doi: 10.14341/DM9686.
Obrezan AG, Kulikov NV. Chronic Heart Failure and Diabetes Mellitus: Pathogenesis and Date of Publication:28-11-2022
Possibilities of Treatment. Kardiologiia. 2018 :58 (7):85-94. (In Russ.) Obrezan A. G., Kulikov N. V. Chronic heart failure and diabetes mellitus: pathogenesis and treatment options. Cardiology. 2018;58(7):85-94, doi: 10.18087/cardio.2018.7.10156.
Yuryeva MY, Dvoryashina IV. Prognostic value of glycemic variability in patients with decompensated chronic heart failure and diabetes mellitus. Kardiologiia. 2017;57(4S):3846. (In Russ.) Yurieva M. Yu., Dvoryashina IV The significance of hyperglycemia and glycemia variability in patients with decompensated chronic heart failure depending on the severity of carbohydrate metabolism disorders. Cardiology. 2017;57(4S):38-46. doi:10.18087/cardio.2403.
Kristensen SL. Mogensen MU, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction). circulation. doi:10.1161/CIRCULATIONAHA.116.024593. 2017 135(8):724-35.
Damman K, Solomon SD, Pfeffer MA, et al. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM study program. European journal of heart failure. 2016;18 (12):1508-17. doi: 10.1002/ejhf.609.
Yang P. Feng J, Peng Q. et al. Advanced Glycation End Products: Potential Mechanism and Therapeutic Target in Cardiovascular Complications under Diabetes. Oxidative Medicine and Cellular Longevity, 2019:2019: 1-12, doi:10.1155/2019/9570616.
Rubler S. Dlugash J. Yuccoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. American Journal of Cardiology. 1972:30 (6):595-602. doi: 10.1016/0002- 9149(72)90595-4.
Lorenzo- Almoros A, Tunon J, Orejas M, et al. Diagnostic approaches for diabetic cardiomyopathy cardiovascular diabetes. 2017;16 (28):1-14. doi: 10.1186/s12933-017-506-x.
Zoungas S, Arima H. Gerstein HC et al. Effects of intensive glucose control on microvascularoutcomes in patients with type 2 diabetes: a meta-analysis of individual trial participant data from randomized controlled trials. The lancet Diabetes & endocrinology. 2017 5 (6):431-7. doi: 10.1016/S2213-8587(17)301043.
American Diabetes Association, 6. Glycemic Targets: Standards of Medical Care in Diabetes - 2020. Diabetes Care. 2020:43 (Suppl. 1):S66-$76. doi: 10.2337/dc20-S006.
AZ Solijonovna. The process of national and spiritual democracy of the personal socialization and its functions// Hunan Daxue Xuebao/Journal of Hunan University Natural Sciences// Vol. 48. No. 12. 2021. 1565-1571湖南大学学报 (自然科学版)。
Solijonovna, Z A. (2020). Modern Information Technologies A Factor Of Increasing Youth https://johuns.net/index.php/abstract/239.html Education. Potential And Spirituality. The American Journal of Social Science and Education Innovations, 2(09), 554-560. https://doi.org/10.37547/tajssei/Volume02Issue09-83
Aripova, Z. S. Informatizing society as one of the reasons for creating a global society / Z. S. Aripova, A. A. Aysachev // кономика и сопиум.-2021. No 4-1(83).-P. 62-65. 20. Aripova, Z. S. Cultural traditions: their essence and structure / Z. S. Aripovа // кономика и Comум.-2020. No 5-1(72).-P. 16-19.
Rosenstock J, Kahn SE, Johansen OD, et al. Effect of linagliptin versus glimepiride major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. Jama. 2019:322 (12):1155-66. doi: 10.1001/jama.2019.13772.
Li J. Tong Y, Zhang Y, et al. Effects on all-cause mortality and cardiovascular outcomes in patients with type 2 diabetes by comparing insulin with oral hypoglycemic agent therapy: a meta-analysis of randomized controlled trials. clinical therapeutics. 2016 :38 (2):372-86. c6.doi:10.1016/j.clinthera.2015.12.006,
Seferovic PM, Petrie MC, Filippatos GS, et al. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European journal of heart failure. 2018 :20 (5):853-72. Doi:10.1002/ejhf.1170.
Pich C. Michalik L. The Janus face of rosiglitazone oncotarget 2018 9 (102)37614-5.Doi:10.18632/oncotarget.26532.
Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. Diabetes & metabolism. 2017:43 (Suppl. 1):2813-2819. Doi: 10.1016/S1262-3636(17)30068-X.
Jia X, Alam M, Ye Y, et al. GLP-1 receptor agonists and cardiovascular disease: a meta-analysis of recent cardiac outcome trials. Cardiovascular drugs and therapy. 2018 :32 (1):65-72. Doi:10.1007/s10557-018-6773-2.
Schernthaner G. Cahn A. Raz L. Is the use of DPP-4 inhibitors associated with an increased risk for heart failure? Lessons from EXAMINE, SAVOR-TIMI 53, and TECOS. Diabetes care. 2016 ; 39 suppl 2):S210-S218. Doi: 10.2337/dcS15-3009.
Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of Cardiovascular outcome trials. The Lancet. 2019 393 (10166):31-9. Doi: 10.1016/S0140 6736(18)32590-X.
Kosiborod M, Cavender MA, Fu AZ, et al. Lower risk of heart failure and death in patients initiated On sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation. 20171 136 (3):249-59. Doi:CIRCULATIONAHA.117.029190.
Marcev VY, Fomin IV. Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure:Chronic (CHF) and acute decompensated (ADIF). Diagnosis, prevention and treatment. Kardiologiia 2018 58 (65):8-158. (In Russ.) Mareev V. Yu., Fomin I. V., Ageev F. T. Et al. Clinical guidelines OSSN-RKO-RNMOT. Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, Prevention and treatment. Cardiology. 2018:58(6):8-158. Doi:10.18087/cardio.2475.
